U.S. Markets closed

Inovio Pharma reports interim results of phase I SynCon flu vaccine

Inovio Pharmaceuticals reported interim results of a phase I trial that showed that a single dose of its H1N1 universal SynCon flu vaccine followed with a dose of a seasonal flu vaccine generated protective immune responses in 40% of trial subjects compared with a 20% response rate in elderly patients who received the seasonal flu vaccine alone. This interim data is a significant step in developing a more effective flu vaccine for the most vulnerable segment of our population.